CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Novo Nordisk (NVO) topped first quarter earnings estimates while its revenue figures came in line with analyst expectations ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...